biologic

Gardasil 9

Human Papillomavirus 9-valent Vaccine, Recombinant

Loss of exclusivityDecember 2026projected — 12-year biologic exclusivity estimate
CompanyMerck Sharp & Dohme LLC

Drug detail

Brand nameGardasil 9
Active ingredientHuman Papillomavirus 9-valent Vaccine, Recombinant
Strength0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalDecember 2014
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gardasil 9 patent cliff — loss of exclusivity December 2026 | CliffBio